КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ: ВРОЖДЕННЫЕ ТРОМБОФИЛИИ КАК ПРИЧИНА РАЗВИТИЯ ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ В МОЛОДОМ ВОЗРАСТЕ

1. Patients with no significant lesions in coronary arteries and ST–segment elevation myocardial infarction have worse outcome than patients with non–ST–segment elevation myocardial infarction: analysis from PL–ACS Registry. Kardiologia Polska, 2010; 68 (11):1211–1217.

2. Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Department of Medical Informatics and Clinical Epidemiology, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR 97239–3098, USA. Mayo Clin Proceedings, 2008;83 (11):1203–12.

3. Guéant-Rodriguez RM, Juilliére Y, Candito M, et al. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost, 2005; 94 (3):510–515.

4. Шахматова О. О., Комаров А. Л., Панченко Е. П. Нарушение обмена гомоцистеина как фактор риска сердечно-сосудистых заболеваний: влияние на прогноз и возможности медикаментозной коррекции. Кардиология, 2010;1:42–50.

5. Klerk M., Verhoef P., Clarke R. et al. and the MTHFR Studies Collaboration Group MTHFR 677C T Polymorphism and Risk of Coronary Heart Disease. JAMA, 2002;288 (16):2023–2031.

6. Joellyn M., Abraham, MD. The homocysteine hypothesis: Still relevant to the prevention and treatment of cardiovascular disease? Cleveland clinic journal of medicine, 2010;77 (12) (201)):911–918.

7. Панченко Е. П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М.: Спорт и культура, 1999:312–326.

8. Данковцева E. Н., Затейщиков Д. A., Сидоренко Б. A. Полиморфизм генов факторов гемостаза у пациентов с ранним развитием ишемической болезни сердца. Кардиология, 2006;2:56–65.

9. Krzysztof C., Tadeusz P., et al. 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with a risk of coronary artery disease, but only in younger people. New Medicine, 2003;3:65–68.

10. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Аtherosclerosis Society (EAS). European Heart Journal (2011), 32:1769–1818.

11. Рекомендации европейского общества кардиологов и европейского общества атеросклероза по лечению дислипидемий. Рациональная фармакотерапия в кардиологии, 2012.

12. Danesh J., Collins R., Peto R.. Lipoprotein (a) and Coronary Heart Disease Meta-Analysis of Prospective Studies. Circulation, 2000. 102:1082–1085.

13. Mega JL, Braunwald E, Wiviott SD et al.// Rivaroxaban in patients with a recent acute coronary syndrome. ATLAS ACS 2–TIMI 51 Investigators. N Engl J Med., 2012, Jan 5. 366 (1):9–19.

14. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика, 2009;8 (6). Приложение 6:163–188.

15. Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal, 2012; 33: 2569–2619.

16. Primary and Secondary Prevention of Cardiovascular Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012;141: e637S-e668S.

17. Guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal, 2012;33:1635–1701.

18. Панченко Е. П., Кропачева Е. С. Профилактика тромбоэмболий у больных мерцательной аритмией. М.: Мед. информ. агентство, 2007. С. 144.

19. Кропачева Е. С. Актуальные вопросы терапии Варфарином для практикующих врачей. РМЖ, 2012;20 (14):686–692.

20. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. P. Borgiani , C. Ciccacci, V. Forte, et al. Pharmacogenomics, 2007;8 (11):1545–1550.

21. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. D. Herman, I. Locatelli, I. Grabnar, et al. Pharmacogenomics J., 2005;5 (3):193–202.

22. Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European Heart Journal, 2012;33:2569–2619.

23. Ежов М. В. Липопротеид (а) и его роль в развитии коронарных осложнений у больных ишемической болезнью сердца. Автореф. дисс. … д-ра мед. наук: 14.01.06, 03.00.04. М., 2009.

24. Bоrge G. Nordestgaard, M. John Chapman et al. Lipoprotein (a) as a cardiovascular risk factor: current status. European Heart Journal, 2010;31:2844–2853.

25. Berglund L, Ramakrishnan R. Lipoprotein (a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol., 2004;24 (12):2219–2226.

26. The AIM-HIGH Study: How it Impacted Our Understanding of HDL Cholesterol in Cardiovascular Health. Dartmouth undergraduate Journal of Science, Accessed 4 November 2011:28–30.

27. Keren A, Goldberg S, Gottlieb S, et al.//Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol., 1990;154:790–800.

28. Osherov AB, Borovik-Raz M, Aronson D, et al.// Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J., 2009;1576:1074–1080.

29. Solheim S, Seljeflot I, Lunde K, et al. Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol., 2010;1069:1197–1200.

30. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a metaanalysis. J Am Coll Cardiol., 1993;224:1004–1009.